Guidelines for the development and validation of new potency assays for the evaluation of umbilical cord blood.
dc.contributor.author | Spellman, Stephen | |
dc.contributor.author | Hurley, Carolyn K | |
dc.contributor.author | Brady, Colleen | |
dc.contributor.author | Phillips-Johnson, Lisa | |
dc.contributor.author | Chow, Robert | |
dc.contributor.author | Laughlin, Mary | |
dc.contributor.author | McMannis, John | |
dc.contributor.author | Reems, Jo-Anna | |
dc.contributor.author | Regan, Donna | |
dc.contributor.author | Rubinstein, Pablo | |
dc.contributor.author | Kurtzberg, Joanne | |
dc.contributor.author | National Marrow Donor Program Cord Blood Advisory Group | |
dc.date.accessioned | 2022-03-23T19:10:55Z | |
dc.date.available | 2022-03-23T19:10:55Z | |
dc.date.issued | 2011-08 | |
dc.date.updated | 2022-03-23T19:10:55Z | |
dc.description.abstract | The following commentary was developed by the National Marrow Donor Program Cord Blood Advisory Group and is intended to provide an overview of umbilical cord blood (UCB) processing, summarize the current state of potency assays used to characterize UCB, and define limitations of the assays and future needs of the cord blood banking and transplant community. The UCB banking industry is eager to participate in the development of standardized assays to uniformly characterize cellular therapy products that are manufactured in a variety of ways. This paper describes the desired qualities of these assays and how the industry proposes to co-operate with developers to bring relevant assays to market. To that end, the National Marrow Donor Program (NMDP) Cord Blood Bank Network is available to serve as a resource for UCB testing material, research and development consulting, and product/assay testing in an accredited UCB manufacturing environment. | |
dc.identifier | S1465-3249(11)70565-5 | |
dc.identifier.issn | 1465-3249 | |
dc.identifier.issn | 1477-2566 | |
dc.identifier.uri | ||
dc.language | eng | |
dc.publisher | Elsevier BV | |
dc.relation.ispartof | Cytotherapy | |
dc.relation.isversionof | 10.3109/14653249.2011.571249 | |
dc.subject | National Marrow Donor Program Cord Blood Advisory Group | |
dc.subject | Fetal Blood | |
dc.subject | Humans | |
dc.subject | Cell Transplantation | |
dc.subject | Biological Assay | |
dc.subject | Reproducibility of Results | |
dc.subject | Blood Banks | |
dc.title | Guidelines for the development and validation of new potency assays for the evaluation of umbilical cord blood. | |
dc.type | Journal article | |
duke.contributor.orcid | Kurtzberg, Joanne|0000-0002-3370-0703 | |
pubs.begin-page | 848 | |
pubs.end-page | 855 | |
pubs.issue | 7 | |
pubs.organisational-group | Duke | |
pubs.organisational-group | School of Medicine | |
pubs.organisational-group | Clinical Science Departments | |
pubs.organisational-group | Institutes and Centers | |
pubs.organisational-group | Pathology | |
pubs.organisational-group | Pediatrics | |
pubs.organisational-group | Duke Cancer Institute | |
pubs.organisational-group | Institutes and Provost's Academic Units | |
pubs.organisational-group | Initiatives | |
pubs.organisational-group | Duke Innovation & Entrepreneurship | |
pubs.organisational-group | Pediatrics, Transplant and Cellular Therapy | |
pubs.publication-status | Published | |
pubs.volume | 13 |
Files
Original bundle
- Name:
- p233 Spellman.pdf
- Size:
- 107.07 KB
- Format:
- Adobe Portable Document Format
- Description:
- Published version